Back to Journals » Eye and Brain » Volume 11

Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity

Authors Patel SN, Klufas MA

Received 14 May 2019

Accepted for publication 25 July 2019

Published 23 August 2019 Volume 2019:11 Pages 25—35


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Margaret Wong-Riley

Samir N Patel, Michael A Klufas

The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, PA, USA

Correspondence: Michael A Klufas
The Retina Service of Wills Eye Hospital, Thomas Jefferson University, 840 Walnut Street, Suite 1020, Philadelphia, PA 19107, USA
Tel +1 800 331 6634
Fax +1 215 825 9087

Abstract: Retinopathy of prematurity (ROP) is a leading and preventable cause of childhood blindness worldwide. Although laser photocoagulation remains the gold standard for treatment, the off-label use of anti-vascular endothelial growth factor (anti-VEGF) therapy to treat ROP, particularly posterior zone I disease, is increasing. Although initial studies on anti-VEGF therapy for ROP have focused on bevacizumab, recent studies have proposed that ranibizumab may be a safer and more effective alternative for use in this population. This review updates recent evidence regarding the use of ranibizumab in the management of ROP.

Keywords: retinopathy of prematurity, ranibizumab, bevacizumab, Lucentis, Avastin, vascular endothelial growth factor, RAINBOW, BEAT-ROP, anti-VEGF

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]